BV for HL: Can the responses last?

Brad S. Kahl

doi:10.1182/blood-2016-08-730374

BV for HL: Can the responses last?

Brad S. Kahl

Research output: Contribution to journal › Comment/debate

Abstract

In this issue of Blood, Chen et al report the long-term follow up from a cohort of relapsed/refractory (R/R) Hodgkin lymphoma (HL) patients, who received single-agent brentuximab vedotin (BV) in a phase 2 pivotal trial, revealing a 5-year overall survival (OS) and 5-year progression-free survival (PFS) of 41% and 22%, respectively (see figure).

Original language	English
Pages (from-to)	1540-1541
Number of pages	2
Journal	Blood
Volume	128
Issue number	12
DOIs	https://doi.org/10.1182/blood-2016-08-730374
State	Published - Sep 22 2016

Access to Document

10.1182/blood-2016-08-730374

Cite this

@article{113f8220561444aab7c763461dca45ae,

title = "BV for HL: Can the responses last?",

abstract = "In this issue of Blood, Chen et al report the long-term follow up from a cohort of relapsed/refractory (R/R) Hodgkin lymphoma (HL) patients, who received single-agent brentuximab vedotin (BV) in a phase 2 pivotal trial, revealing a 5-year overall survival (OS) and 5-year progression-free survival (PFS) of 41\% and 22\%, respectively (see figure).",

author = "Kahl, \{Brad S.\}",

note = "Publisher Copyright: {\textcopyright} 2016 by The American Society of Hematology.",

year = "2016",

month = sep,

day = "22",

doi = "10.1182/blood-2016-08-730374",

language = "English",

volume = "128",

pages = "1540--1541",

journal = "Blood",

issn = "0006-4971",

number = "12",

}

TY - JOUR

T1 - BV for HL

T2 - Can the responses last?

AU - Kahl, Brad S.

PY - 2016/9/22

Y1 - 2016/9/22

N2 - In this issue of Blood, Chen et al report the long-term follow up from a cohort of relapsed/refractory (R/R) Hodgkin lymphoma (HL) patients, who received single-agent brentuximab vedotin (BV) in a phase 2 pivotal trial, revealing a 5-year overall survival (OS) and 5-year progression-free survival (PFS) of 41% and 22%, respectively (see figure).

AB - In this issue of Blood, Chen et al report the long-term follow up from a cohort of relapsed/refractory (R/R) Hodgkin lymphoma (HL) patients, who received single-agent brentuximab vedotin (BV) in a phase 2 pivotal trial, revealing a 5-year overall survival (OS) and 5-year progression-free survival (PFS) of 41% and 22%, respectively (see figure).

UR - https://www.scopus.com/pages/publications/84988708783

U2 - 10.1182/blood-2016-08-730374

DO - 10.1182/blood-2016-08-730374

M3 - Comment/debate

C2 - 27658697

AN - SCOPUS:84988708783

SN - 0006-4971

VL - 128

SP - 1540

EP - 1541

JO - Blood

JF - Blood

IS - 12

ER -

BV for HL: Can the responses last?

Abstract

Access to Document

Other files and links

Fingerprint

Cite this